Gilead Sciences’ $7.8bn Acquisition of Arcellx
- 5 days ago
- 6 min read
By Blanche Delaunay, Huseyn Badalbayli, Kristiyan Nedelchev, Martin Tropchev, and Robin van der Werf (Rotterdam School of Management); Gilles Michaud and Marc Bellon (HEC Paris)
Photo: Louis Reed (Unsplash)
Overview of the deal
Acquirer: Gilead Sciences, Inc. (Nasdaq: GILD)
Target: Arcellx, Inc. (Nasdaq: ACLX)
Implied Equity Value: $7.8 billion ($115 per share in cash + $5 CVR per share)
Total Transaction Size: $7.8 billion
Closed Date: April 28, 2026
Target Advisor: Centerview Partners LLC (financial), Wilson Sonsini Goodrich & Rosati, P.C. (legal)
Acquirer Advisor: BofA Securities, Inc. and Morgan Stanley & Co. LLC (financial), Ropes & Gray LLP (legal)
Gilead Sciences' $7.8 billion acquisition of Arcellx represents a strategic consolidation of the companies' existing collaboration into full ownership, anchored by anitocabtagene autoleucel (anito-cel), a next-generation BCMA-directed CAR-T cell therapy for relapsed or refractory multiple myeloma with a PDUFA date in December 2026. Gilead aims to meaningfully improve the long-term economics of the asset by eliminating future profit-sharing, milestone payments, and royalty obligations under the prior Kite Pharma collaboration agreement.
Moreover, anito-cel is seen as a direct competitor to Johnson & Johnson's Carvykti, and so full ownership benefits Gilead, by removing co-development constraints, thus allowing it to accelerate commercialization. Beyond the lead asset, Gilead gains full rights to Arcellx's proprietary D-domain CAR-T platform, which gives it the ability to create future drugs using an already established base. Strategically, the transaction reinforces Gilead's pivot toward high-growth oncology to offset revenue pressures in its maturing antiviral franchises, with management expecting EPS accretion from 2028 onward following anticipated FDA approval.
Company Details (Acquirer - Gilead Sciences)
Gilead Sciences is a biopharmaceutical company that develops and sells innovative medicines for serious diseases. Their three main areas are HIV/viral hepatitis, cancer, and inflammation. Gilead is the world leader in HIV treatment, providing medications to millions of patients globally. The company also has a strong oncology portfolio including CAR-T cell therapies for blood cancers. Gilead operates in over 35 countries and focuses on bringing curative treatments to patients through both internal research and acquisitions.
Founded: 1987
Headquartered: Foster City, California, USA
CEO: Daniel O'Day
Number of employees: 17,000+
Market Cap*: $159,92 billion
EV: $175.24 billion USD
LTM Revenue: $29.44 billion USD
LTM EBITDA: $14.58 billion USD
LTM EV/Revenue: 5.95X
LTM EV/EBITDA: 12.02X
*As of 29/04/2026
Recent Transactions: $7.8bn acquisition of Arcellx (Apr 2026); $5bn acquisition of Tubulis (Apr 2026); $2.18bn acquisition of Ouro Medicines (Mar 2026)
Company Details (Target - Arcellx)
Arcellx is a clinical-stage biotechnology company developing innovative cell therapies for cancer patients. Founded in 2014 in Gaithersburg, Maryland, the company specializes in a cutting-edge approach called CAR-T therapy, which works by reprogramming a patient's own immune cells to recognize and attack cancer. Arcellx developed a proprietary technology platform that aims to make these treatments safer and easier to manufacture than existing alternatives. Its lead drug candidate, anito-cel, targets multiple myeloma, one of the most common forms of blood cancer, and is currently under FDA review with a decision expected by December 2026. In clinical trials, anito-cel showed a 96% response rate and, importantly, none of the serious neurological side effects observed with competing therapies already on the market. Prior to the acquisition, Arcellx had been collaborating with Gilead's Kite Pharma since 2022 to bring anito-cel to patients.
Founded: 2014
Headquartered: Redwood City, California, USA
CEO: Rami Elghandour
Number of employees: 200
Market Cap*: $3.71 billion
EV: N/A
LTM Revenue*: $35.9 million USD
LTM EBITDA: N/A
LTM EV/Revenue: N/A
LTM EV/EBITDA: N/A
*As of 20/02/2026
Projections and Assumptions
Short-Term Consequences
In the short term, Gilead’s acquisition of Arcellx is expected to have a clearly dilutive impact on earnings, as upfront transaction costs, integration expenses, and continued investment in clinical development weigh on profitability. As a result, EPS is expected to decline by approximately $5.6 per share in 2026. This near-term dilution appears to already be largely anticipated by investors, particularly in light of Gilead’s broader acquisition strategy, including multiple recent transactions with a combined value of approximately $15 billion.
In biotech deals, value is tied to future commercialization rather than immediate cash flows. At the same time, the transaction strengthens Gilead’s product offering by bringing full control over Arcellx’s lead CAR-T therapy, anito-cel, targeting a multiple myeloma market estimated at over $20 billion. While this does not generate immediate revenues, it enhances Gilead’s oncology pipeline and accelerates its positioning in advanced cancer treatments.
From an operational perspective, the short-term focus will be on integrating Arcellx into Gilead’s existing cell therapy platform, including manufacturing scale-up and clinical trial alignment. Leadership attention will also be directed toward retaining key scientific talent and ensuring continuity in ongoing research, as disruptions at this stage could delay development timelines.
Geographically, the impact is limited in the immediate term, as both companies already operate within global biotech networks. The most visible short-term effect has been the market reaction - Arcellx’s share price increased from around $64 to approximately $115, reflecting a premium of nearly 80%, while Gilead’s stock declined modestly amid concerns over near-term dilution and execution risk.
Long-Term Upsides
The acquisition of Arcellx represents a decisive move by Gilead to take full ownership of what could become the leading treatment for multiple myeloma, one of the most common blood cancers, in a market estimated at over $15 billion in the United States alone. Until now, the two companies had been partners on developing anito-cel, sharing profits and decision-making. By acquiring Arcellx outright, Gilead eliminates all future profit-sharing and royalty obligations, allowing it to capture the full financial upside of the drug going forward.
Moreover, anito-cel has shown strong potential to stand out in a competitive field. In clinical trials, the therapy achieved a 96% response rate and, critically, none of the serious neurological side effects such as Parkinsonism that have been linked to Johnson & Johnson's rival treatment Carvykti, which generated over $1.8 billion in revenue in 2025. This superior safety profile, combined with Gilead's existing manufacturing capabilities through its Kite division, could make it easier for doctors to prescribe the treatment and even administer it in outpatient settings rather than specialized hospitals.
Beyond the initial launch, Gilead is also testing anito-cel in patients at earlier stages of the disease through a Phase 3 trial. If successful, this would considerably expand the number of eligible patients. Combined with Arcellx's broader technology platform and earlier-stage drug programs, the deal gives Gilead both a near-term revenue driver and a foundation for long-term growth in cell therapy.
Risks and Uncertainties
The most immediate risk is regulatory. Although the FDA has accepted Arcellx's application for anito-cel, approval is not guaranteed. Any issues identified during the review, whether related to clinical results, manufacturing quality, or safety monitoring requirements, could delay or block the expected launch in late 2026, calling into question the rationale behind the $7.8 billion price tag.
In parallel, the competitive environment is becoming increasingly challenging. Johnson & Johnson's Carvykti has been on the market since 2022 and is projected to reach peak sales of approximately $7 billion by 2030. While anito-cel offers a better safety profile, its effectiveness appears broadly similar based on available data. Persuading doctors and insurance companies to switch to a newer, unproven alternative will therefore require substantial commercial effort and convincing real-world evidence over time.
At the same time, the deal weighs on Gilead's near-term profitability. The company expects the transaction to reduce its 2026 earnings per share by approximately $5.57 to $5.67, and does not anticipate the acquisition becoming profitable until 2028 at the earliest, assuming the drug receives FDA approval and launches successfully. Finally, CAR-T treatments are inherently complex to produce, as each dose must be individually manufactured from a patient's own cells. Any production bottlenecks during the critical launch period could limit patient access and slow revenue growth.
“With the Arcellx acquisition, our focus turns to executing with speed and discipline as we prepare to bring anito‑cel to patients.” Cindy Perettie, Vice President and Global Head of Kite (Kite, Gilead Sciences).
Sources